(ORGO) Organogenesis Holdings - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 342m USD | Total Return: -9.8% in 12m
Avg Turnover: 3.77M
Qual. Beats: -1
Rev. Trend: 62.4%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Organogenesis Holdings Inc. is a Massachusetts-based regenerative medicine company specializing in the development and commercialization of bioactive products for advanced wound care, surgical, and sports medicine markets. Their portfolio includes bioengineered skin substitutes like Apligraf and Dermagraft, placental allografts such as Affinity and NuShield, and antimicrobial barriers for chronic and acute wound management. The company is also expanding into orthopedics with ReNu, a Phase 3 trial candidate for knee osteoarthritis.
The company operates within the biotechnology sector, utilizing a vertically integrated business model that encompasses internal manufacturing and a direct sales force targeting hospitals and specialized wound care centers. Advanced wound care is a critical segment driven by the rising global prevalence of diabetes and an aging population, which increases the incidence of chronic ulcers. For a deeper look at the underlying fundamentals, check out ValueRay.
Distribution is managed through a network of direct sales representatives and independent agencies serving diverse clinical settings, including ambulatory service centers and government facilities. The company focuses on extracellular matrix (ECM) scaffolds and tissue-engineered products that promote native healing processes in complex surgical and dermatological applications.
- Medicare reimbursement policy changes impact advanced wound care product pricing and volume
- ReNu Phase 3 clinical trial results determine entry into osteoarthritis market
- Sales force productivity and expansion drive market share in surgical settings
- Regulatory scrutiny of placental-derived allografts affects long-term product availability and revenue
- High concentration of revenue from bioengineered skin substitutes creates sensitivity to competition
| Net Income: -284k TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 4.78 > 1.0 |
| NWC/Revenue: 37.48% < 20% (prev 44.27%; Δ -6.79% < -1%) |
| CFO/TA 0.06 > 3% & CFO 30.8m > Net Income -284k |
| Net Debt (-21.2m) to EBITDA (44.0m): -0.48 < 3 |
| Current Ratio: 3.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (127.8m) vs 12m ago 1.19% < -2% |
| Gross Margin: 70.41% > 18% (prev 0.76%; Δ 6.97k% > 0.5%) |
| Asset Turnover: 104.0% > 50% (prev 98.15%; Δ 5.87% > 0%) |
| Interest Coverage Ratio: 8.34 > 6 (EBITDA TTM 44.0m / Interest Expense TTM 1.32m) |
| A: 0.37 (Total Current Assets 268.5m - Total Current Liabilities 76.0m) / Total Assets 520.0m |
| B: -0.11 (Retained Earnings -56.2m / Total Assets 520.0m) |
| C: 0.02 (EBIT TTM 11.0m / Avg Total Assets 493.7m) |
| D: -0.41 (Book Value of Equity -56.2m / Total Liabilities 138.6m) |
| Altman-Z'' = 1.80 = BBB |
| DSRI: 1.01 (Receivables 116.9m/103.3m, Revenue 513.6m/458.8m) |
| GMI: 1.08 (GM 70.41% / 75.85%) |
| AQI: 0.97 (AQ_t 0.18 / AQ_t-1 0.19) |
| SGI: 1.12 (Revenue 513.6m / 458.8m) |
| TATA: -0.06 (NI -284k - CFO 30.8m) / TA 520.0m) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of May 30, 2026, the stock is trading at USD 2.57 with a total of 925,418 shares traded.
Over the past week, the price has changed by -3.38%,
over one month by +11.74%,
over three months by -19.94% and
over the past year by -9.82%.
Organogenesis Holdings has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ORGO.
- StrongBuy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 8 | 211.3% |
P/E Forward = 12.6743
P/S = 0.665
P/B = 1.3996
Revenue TTM = 513.6m USD
EBIT TTM = 11.0m USD
EBITDA TTM = 44.0m USD
Long Term Debt = 61.1m USD (estimated: total debt 70.9m - short term 9.72m)
Short Term Debt = 9.72m USD (from shortTermDebt, last quarter)
Debt = 70.9m USD (from shortLongTermDebtTotal, last quarter) (leases 70.9m already included)
Net Debt = -21.2m USD (calculated: Debt 70.9m - CCE 92.1m)
Enterprise Value = 321.0m USD (342.3m + Debt 70.9m - CCE 92.1m)
Interest Coverage Ratio = 8.34 (Ebit TTM 11.0m / Interest Expense TTM 1.32m)
EV/FCF = 18.79x (Enterprise Value 321.0m / FCF TTM 17.1m)
FCF Yield = 5.32% (FCF TTM 17.1m / Enterprise Value 321.0m)
FCF Margin = 3.33% (FCF TTM 17.1m / Revenue TTM 513.6m)
Net Margin = -0.06% (Net Income TTM -284k / Revenue TTM 513.6m)
Gross Margin = 70.41% ((Revenue TTM 513.6m - Cost of Revenue TTM 151.9m) / Revenue TTM)
Gross Margin QoQ = -2.46% (prev 77.82%)
Tobins Q-Ratio = 0.62 (Enterprise Value 321.0m / Total Assets 520.0m)
Interest Expense / Debt = 1.86% (Interest Expense 1.32m / Debt 70.9m)
Taxrate = 21.16% (9.94m / 47.0m)
NOPAT = 8.68m (EBIT 11.0m * (1 - 21.16%))
Current Ratio = 3.53 (Total Current Assets 268.5m / Total Current Liabilities 76.0m)
Debt / Equity = 0.19 (Debt 70.9m / totalStockholderEquity, last quarter 381.3m)
Debt / EBITDA = -0.48 (Net Debt -21.2m / EBITDA 44.0m)
Debt / FCF = -1.24 (Net Debt -21.2m / FCF TTM 17.1m)
Total Stockholder Equity = 390.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.06% (Net Income -284k / Total Assets 520.0m)
RoE = -0.06% (Net Income TTM -284k / Total Stockholder Equity 446.8m)
RoCE = 2.17% (EBIT 11.0m / Capital Employed (Equity 446.8m + L.T.Debt 61.1m))
RoIC = 1.91% (NOPAT 8.68m / Invested Capital 453.7m)
WACC = 8.36% (E(342.3m)/V(413.1m) * Re(9.79%) + D(70.9m)/V(413.1m) * Rd(1.86%) * (1-Tc(0.21)))
Discount Rate = 9.79% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -15.56 | Cagr: -1.38%
[DCF] Terminal Value 75.39% ; FCFF base≈17.1m ; Y1≈17.2m ; Y5≈18.2m
[DCF] Fair Price = 2.36 (EV 282.0m - Net Debt -21.2m = Equity 303.2m / Shares 128.7m; r=8.36% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.75 | # QB: -1
Revenue Correlation: 62.35 | Revenue CAGR: 5.54% | SUE: -0.34 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.30 | Chg30d=-233.33% | Revisions=-20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.12 | Chg30d=-220.00% | Revisions=-20% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.74 | Chg30d=-335.29% | Revisions=-20% | GrowthEPS=-274.7% | GrowthRev=-50.1%
EPS next Year (2027-12-31): EPS=-0.23 | Chg30d=-179.31% | Revisions=-20% | GrowthEPS=+68.9% | GrowthRev=+22.0%